QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
NASDAQ:SBTX

Silverback Therapeutics Stock Forecast, Price & News

$9.50
+0.12 (+1.28 %)
(As of 10/19/2021 04:00 PM ET)
Add
Compare
Today's Range
$9.27
$9.62
50-Day Range
$9.22
$30.91
52-Week Range
$9.10
$63.41
Volume208,119 shs
Average Volume257,122 shs
Market Capitalization$332.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Silverback Therapeutics logo

About Silverback Therapeutics

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical Preparation Manufacturing
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SBTX
Phone
N/A
Employees
54
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$332.84 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

204th out of 1,361 stocks

Pharmaceutical Preparation Manufacturing Industry

1st out of 4 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Silverback Therapeutics (NASDAQ:SBTX) Frequently Asked Questions

Is Silverback Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silverback Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Silverback Therapeutics stock.
View analyst ratings for Silverback Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Silverback Therapeutics?

Wall Street analysts have given Silverback Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Silverback Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Silverback Therapeutics' next earnings date?

Silverback Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Silverback Therapeutics
.

How were Silverback Therapeutics' earnings last quarter?

Silverback Therapeutics, Inc. (NASDAQ:SBTX) issued its quarterly earnings results on Thursday, August, 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.16.
View Silverback Therapeutics' earnings history
.

What price target have analysts set for SBTX?

5 equities research analysts have issued 1 year price targets for Silverback Therapeutics' stock. Their forecasts range from $48.00 to $60.00. On average, they expect Silverback Therapeutics' share price to reach $51.80 in the next twelve months. This suggests a possible upside of 445.3% from the stock's current price.
View analysts' price targets for Silverback Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Silverback Therapeutics' key executives?

Silverback Therapeutics' management team includes the following people:
  • Dr. Peter A. Thompson M.D., Co-Founder & Chairman of Directors (Age 61, Pay $5.12k)
  • Dr. Laura K. Shawver, CEO & Director (Age 63, Pay $786.65k)
  • Dr. Valerie Odegard Ph.D., Pres & Chief Scientific Officer (Age 44, Pay $552.38k)
  • Mr. Jonathan Piazza, Chief Financial Officer (Age 45, Pay $299.89k)
  • Mr. Jeffrey C. Pepe J.D., Ph.D., Sr. VP & Gen. Counsel
  • Katie Carrigan, VP of HR
  • Dr. Naomi Hunder M.D., Chief Medical Officer (Age 52)
  • Mr. Russ Hawkinson, Sr. VP of Fin.
  • Mr. Scott Moorefield Ph.D., Sr. VP of Bus. Devel.
  • Mr. Sateesh Natarajan, Sr. VP of CMC Devel.

When did Silverback Therapeutics IPO?

(SBTX) raised $126 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager.

What is Silverback Therapeutics' stock symbol?

Silverback Therapeutics trades on the NASDAQ under the ticker symbol "SBTX."

Who are Silverback Therapeutics' major shareholders?

Silverback Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Hohimer Wealth Management LLC (0.05%). Company insiders that own Silverback Therapeutics stock include Jonathan Piazza, Presidio Management Group Xii,, Russ Hawkinson and Vickie L Capps.
View institutional ownership trends for Silverback Therapeutics
.

Which institutional investors are buying Silverback Therapeutics stock?

SBTX stock was bought by a variety of institutional investors in the last quarter, including Hohimer Wealth Management LLC. Company insiders that have bought Silverback Therapeutics stock in the last two years include Jonathan Piazza, Presidio Management Group Xii,, Russ Hawkinson, and Vickie L Capps.
View insider buying and selling activity for Silverback Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Silverback Therapeutics?

Shares of SBTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Silverback Therapeutics' stock price today?

One share of SBTX stock can currently be purchased for approximately $9.50.

How much money does Silverback Therapeutics make?

Silverback Therapeutics has a market capitalization of $332.84 million.

How many employees does Silverback Therapeutics have?

Silverback Therapeutics employs 54 workers across the globe.

What is Silverback Therapeutics' official website?

The official website for Silverback Therapeutics is www.silverbacktx.com.


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.